Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Meningococcal Vaccines Market Growth in 2025?

The market for meningococcal vaccines has experienced rapid expansion in the past few years. It’s projected to rise from $3.89 billion in 2024 to $4.29 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. Factors contributing to growth during this historical period include the frequency of the disease, global travel patterns, the quality of healthcare infrastructure, epidemic readiness, and the scope of health insurance coverage.

What Is the Forecast for the Meningococcal Vaccines Market Size Through 2029?

The market size for meningococcal vaccines is anticipated to exhibit robust growth in the upcoming years, with projections suggesting a rise to $6.18 billion by 2029. This surges at a compound annual growth rate (CAGR) of 9.5%. Factors contributing to growth in the projected period include the emergence of new strains, increased globalization, escalating healthcare investments, health initiatives, and an evolving regulatory environment. Notable market trends during the forecast period include the development of personalized vaccines, the emergence of digital vaccination records, gene editing technologies, multi-valent vaccines, and subscription-based vaccine models.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What are the Key Market Players in Meningococcal Vaccines Market and How They’re Evolving?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

What Are the Primary Growth Drivers in the Meningococcal Vaccines Market?

The meningococcal vaccine market is expected to expand due to projected rise in healthcare expenditures. Healthcare implies an array of medical care facilities, including residential care institutions, nursing homes, and intermediate care facilities for individuals with mental disorders or impairments. The substantial cost of newer vaccine generations in comparison to older ones has ignited debates concerning the justification of these high prices against their benefits. Evaluating the comprehensive societal and economical benefits of vaccines is gaining increased scholarly interest in vaccination value studies. For example, a May 2022 report by the American Medical Association, a renowned organization composed of physicians and medical students in the U.S, revealed that the country’s healthcare spending had surged by 9.7% to $4.1 trillion or $12,530 per capita. This growth rate is distinctly more significant than that recorded in 2019 (4.3%). Thus, higher healthcare spending is contributing to the progression of the meningococcal vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

What Are the Leading Segments in the Global Meningococcal Vaccines Industry?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

What Are the Key Market Trends in the Meningococcal Vaccines Industry?

Prominent corporations in the meningococcal vaccines industry are focusing on the creation of new vaccines for the prevention of specific serogroups to boost their market profitability. Meningococcal vaccines serve as preventative defense mechanisms against infections caused by distinct serogroups of the Neisseria meningitidis bacteria. For illustration, in October 2023, Pfizer Inc., a pharmaceutical firm based out of the United States, obtained FDA authorization for its vaccine, PENBRAYA. With a broad range of serogroup coverage, PENBRAYA positions as the most comprehensive meningococcal vaccine sanctioned in the U.S., providing safety against A, B, C, W, and Y groups. The FDA endorsement is based on substantial Phase 2 and 3 trial information, verifying the vaccine’s immunogenicity, equal to Trumenba + Menveo across all serogroups, along with a favorable safety record. A recent announcement in September 2022 from Pfizer shared encouraging results from a Phase 3 trial where PENBRAYA was compared with other licensed meningococcal vaccines, evaluating safety, tolerability, and immunogenicity.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

What Is the Regional Outlook for the Meningococcal Vaccines Market?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8013

This Report Delivers Insight On:

1. How big is the meningococcal vaccines market, and how is it changing globally?

2. Who are the major companies in the meningococcal vaccines market, and how are they performing?

3. What are the key opportunities and risks in the meningococcal vaccines market right now?

4. Which products or customer segments are growing the most in the meningococcal vaccines market?

5. What factors are helping or slowing down the growth of the meningococcal vaccines market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model